Schoch J
Fortschr Med. 1975 Jan 23;93(3):133-6.
The clinical effectiveness of an anti-arthrotic drug was investigated in a comparative trial. 106 patients suffering from moderate arthrosis of the knee were placed into two groups in accordance with a random table and treated by intramuscular injection of Arteparon forte or an analogous control product. The criteria of assessment were pain on movement, pain at rest, limitation of active and of passive movement. The number of patients who at the end of treatment and at the time of follow up, three months later, had no or insignificant residual symptoms and signs, were greater in the Arteparon forte group than in the control group. This difference was statistically significant two months after the beginning of treatment for the criterion pain at rest, and five months after beginning of treatment for all criteria. A global assessment of the results was carried out according to the number of pronouncedly improved criteria in the individual patients. According to this assessment, the results of treatment at the termination of treatment amounted to 73.6% in the Arteparon forte group and 56.6% in the control group. At the time of follow up the corresponding value of the Arteparon forte group was 68.4%, thus significantly greater than that of the control group (29.4%).
在一项对比试验中研究了一种抗关节炎药物的临床疗效。106名患有中度膝关节骨性关节炎的患者根据随机表被分为两组,分别通过肌肉注射Arteparon forte或一种类似的对照产品进行治疗。评估标准为运动时疼痛、静息时疼痛、主动和被动运动受限。在治疗结束时以及三个月后的随访时,无或仅有轻微残留症状和体征的患者数量,Arteparon forte组比对照组更多。对于静息时疼痛这一标准,在治疗开始两个月后这种差异具有统计学意义,对于所有标准,在治疗开始五个月后差异具有统计学意义。根据个体患者中明显改善的标准数量对结果进行整体评估。根据该评估,治疗结束时Arteparon forte组的治疗有效率为73.6%,对照组为56.6%。在随访时,Arteparon forte组的相应数值为68.4%,因此显著高于对照组(29.4%)。